Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclectin is a fixed-dose combination of doxylamine succinate, a first-generation antihistamine, and pyridoxine hydrochloride, a form of vitamin B6. It is specifically indicated for the treatment of nausea and vomiting of pregnancy (NVP) in women who do not respond to conservative management. Doxylamine acts as a competitive antagonist at the H1 receptor and also possesses significant anticholinergic activity, which contributes to its antiemetic properties. Pyridoxine is a water-soluble vitamin that serves as a cofactor in numerous enzymatic reactions, including those involving neurotransmitter synthesis, which may help alleviate pregnancy-related nausea. The drug is formulated as a delayed-release tablet to provide consistent relief. Xiaoke Wu led a significant clinical trial investigating its efficacy alongside acupuncture for moderate to severe NVP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on doxylamine + pyridoxine.